Also DXB into H2 2019 trials and ATX as an early stage name, once CR out of the way and into next year. PXS the other one on my watchlist.
Focussed more on the startups right now tbh and following the AI/bio link and personalised medicine. A CRISP project would possibly break the ASX if it listed here but the patent situation makes it unlikely in the next few years.
